KNTE Insider Trading Activity and SEC Form 4 Filings
KNTE insider trading summary
No open-market insider purchases or sales of Kinnate Biopharma Inc. (KNTE) have been reported on SEC Form 4 in the past 12 months.
Latest KNTE insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| May 8, 2023 | Foresite Capital Opportunity Fund V, L.P. | 10% Owner | Buy | $4.3M (1,550,956 @ $2.80) |
| May 8, 2023 | Foresite Capital Management V, LLC | 10% Owner | Buy | $4.3M (1,550,956 @ $2.80) |
| May 8, 2023 | Foresite Capital Management IV, LLC | 10% Owner | Buy | $4.3M (1,550,956 @ $2.80) |
| May 8, 2023 | Foresite Capital Fund V, L.P. | 10% Owner | Buy | $4.3M (1,550,956 @ $2.80) |
| May 8, 2023 | Foresite Capital Opportunity Management V, LLC | 10% Owner | Buy | $4.3M (1,550,956 @ $2.80) |
| May 8, 2023 | Foresite Capital Management IV, LLC | 10% Owner | Buy | $641K (229,044 @ $2.80) |
| May 8, 2023 | James B. Tananbaum | Director | Buy | $641K (229,044 @ $2.80) |
| May 8, 2023 | James B. Tananbaum | Director | Buy | $4.3M (1,550,956 @ $2.80) |
| May 8, 2023 | Foresite Capital Fund IV, L.P. | 10% Owner | Buy | $4.3M (1,550,956 @ $2.80) |
| May 8, 2023 | Foresite Capital Fund IV, L.P. | 10% Owner | Buy | $641K (229,044 @ $2.80) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.